Please Wait
Applying Filters...
menu
    • menu

    List of Written Confirmation(s) issued for MolPort-001-641-065 Active Pharmaceutical Ingredient (API)

    Client Email Product
    US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    MolPort-001-641-065

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 47Xls download

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Name of the Firm Written Confirmation No. Product Name Issue Date Valid Till Address of the Firm
    30/05/2020 Ipca Laboratories
    India
    		 M/s.  IPCA Laboratories Ltd.,  WC-0091 Furosemide ((BP/JP/ Ph.Eur) 2022-06-08 2025-07-02 Sejavta, Ratlam, Madhya Pradesh 
    08/06/2021 Mangalam Drugs & Organics Ltd
    India
    		 M/s Mangalam Drugs and Organics Ltd WC-0167 Furosemide IP/BP/EP/USP 2022-10-27 2025-07-22 Unit No.1, Plot No.187, IInd Phase, GIDC Vapi-396195, Dist-Valsad, India